Cowen initiates coverage on Aduro Biotech (NASDAQ: ADRO) with a Outperform rating.Analyst Dr. Chris Shibutani believes the companies distinct immune-oncology ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE